[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin,2018,68:394-424.
[2] 安澜,曾红梅,郑荣寿,等. 2015年中国肝癌流行情况分析. 中华肿瘤杂志,2019,41:721-727.
[3] Zhang Z, Lai ECH, Zhang C, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg,2015,20:8-16.
[4] Cheng S, Chen M, Cai J, et al. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 Edition). Liver Cancer,2020,9:28-40.
[5] 程树群,吴孟超,陈汉,等. 肝癌门静脉癌栓分型的影像学意义. 中华普通外科杂志,2004:6-7.
[6] Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol,2018,69:182-236.
[7] Benson AB, D'Angelica MI, Abbott D E, et al. NCCN Guidelines:Hepatobiliary Cancers,Version1.2020.https://www.nccn.org/professionals/physician_gls/default.aspx#hepatobiliary
[8] 何其宽,叶志宇,陈晓岗. 肝癌免疫微环境及免疫治疗最新进展. 肝胆胰外科杂志,2019,31:705-709.
[9] Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity,2013,39:1-10.
[10] Mocan T, Sparchez Z, Craciun R, et al. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol,2019,21:702-712.
[11] Ganesan A, Moon TC, Barakat KH. Revealing the atomistic details behind the binding of B7–1 to CD28 and CTLA-4: a comprehensive protein-protein modelling study. Biochim Biophys Acta Gen Subj,2018,1862:2764-2778.
[12] El-Khoueiry ABD, Sangro BM, Yau T M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet,2017,389:2492-2502.
[13] Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase ii and phase iii trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol,2015,33:1889-1894.
[14] Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol,2013,59:81-88.
[15] Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol,2017,66:545-551.
[16] Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol,2019,30:v874-v875.
[17] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol,2018,19:940-952.
[18] Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in keynote-240: a randomized, double-blind, phase III trial. J Clin Oncol,2020,38:193-202.
[19] Wainberg ZA, Segal NH, Jaeger D, et al. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC). J Clin Oncol,2017,35:4071.
[20] Yau T, Kang Y, Kim T, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. J Clin Oncol,2019,37:4012.
[21] Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis,2018,9:114-115.
[22] Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. Angiogenesis,2017,20:185-204.
[23] Cheng AL, Qin S, Ikeda M, et al. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol,2019,30:x186-x187.
[24] Adachi Y, Matsuki M, Watanabe H, et al. Antitumor and antiangiogenic activities of lenvatinib in mouse xenograft models of vascular endothelial growth factor-induced hypervascular human hepatocellular carcinoma. Cancer Invest,2019,37:185-198.
[25] Llovet J, Shepard KV, Finn RS, et al. A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results. Ann Oncol,2019,30:v286-v287.
[26] Kudo M, Ikeda M, Motomura K, et al. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): study 117. J Clin Oncol,2020,38:513.
[27] Greten TF, Mauda-Havakuk M, Heinrich B, et al. Combined locoregional-immunotherapy for liver cancer. J Hepatol,2019,70:999-1007.
[28] Ding M, Wang Y, Chi J, et al. Is adjuvant cellular immunotherapy essential after tace-predominant minimally-invasive treatment for hepatocellular carcinoma? a systematic meta-analysis of studies including 1774 patients. PLoS One,2016,11:e168798.
[29] Pinato DJ, Cole T, Bengsch B, et al. A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL. Ann Oncol,2019,30:v288. |
